Sign in
Taking people in United StatesPhase 4

Zynrelef compared with usual pain treatments after knee replacement for knee osteoarthritis

Compares Zynrelef with a nerve block or standard injection after knee replacement.

Key facts

Who runs it
Henry Ford Health System
Where
Grosse Pointe Farms, United StatesSee the site
Trial code
Registry title
Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty
Status
Recruiting
Phase
Phase 4
People taking part
150 people, planned
Started
11 Feb 2025
Planned end
20 Oct 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Periarticular Injection
  • Adductor Canal Block
  • Bupivacaine-Meloxicam
Record updated
20 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults having a first total knee replacement at Henry Ford Health System, planned to go home the same day. It compares three ways to control pain after surgery.

Age
18 years and older
Sex
All sexes
Disease stage
Knee osteoarthritis needing a primary (first) total knee replacement on one knee, with planned same-day discharge.
Earlier treatment
People who used opioids long-term in the last 3 months, or had surgery on a joint on the same side in the last year, cannot join.

Main reasons for not taking part

  • Replacement of both knees at once
  • Cannot take medicines by mouth, or has trouble swallowing
  • Cannot tolerate acetaminophen, anti-inflammatories, muscle relaxants, gabapentinoids, or opioids/tramadol
  • History of alcohol or drug abuse, or illegal narcotic use in the past 6 months
  • Kidney problems, peptic ulcer, stomach or gut bleeding, chronic liver disease, chronic pain syndromes, or not speaking English

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adult patients age 18 and older undergoing primary total knee replacement by fellowship trained Orthopedic Surgeons in Henry Ford Health System with planned outpatient same-day discharge

Who cannot take part

  • Ipsilateral joint surgery in the last year
  • Cannot tolerate oral medications
  • Drug abuse
  • History of alcohol abuse
  • Renal impairment
  • Peptic ulcer disease
  • GI bleeding
  • Chronic liver disease
  • Chronic pain syndromes
  • Incomplete data in medical records
  • Non-English speakers
  • Chronic opioid use in the last 3 months
  • Undergoing bilateral knee arthroplasty
  • Swallowing difficulties
  • Intolerance to acetaminophen, anti-inflammatories, muscle relaxants, gabapentinoids, or opioids/tramadol
  • Illicit narcotic usage in the past 6 months

Where in United States

  • Henry Ford Medical Center - Grosse Pointe CottageGrosse Pointe Farms, United StatesContact: Trevor North, MDTaking people

About the trial

What the trial wants to find out

Participants are being invited to take part in a research study about pain control after total knee replacement surgery (also called total knee arthroplasty or TKA). The goal of this study is to see if a new long-acting medication, called Zynrelef, can control pain after surgery as well as or better than two other common pain treatments - a nerve block or a standard injection into the knee during surgery.

Read full original descriptionShow less

Knee replacement is done to reduce pain and improve movement in people with severe knee arthritis. While the surgery can be very successful, pain during the first few days after surgery can make recovery harder. Many patients need strong opioid pain medicines, but these medicines can have side effects and may lead to dependence. The investigators want to find ways to control pain that reduce or even remove the need for opioids.

If participants join this study, they will be randomly placed (like flipping a coin) into one of three groups:

Standard injection (PAI) - a mix of medicines injected into the knee during surgery.

Zynrelef - a new long-acting medicine put directly into the knee during surgery, along with a smaller dose of the standard injection.

Nerve block (ACB) - medicine given near a nerve in the leg before surgery to block pain.

All participants will get the same medicines before and after surgery, follow the same physical therapy program, and have the same follow-up visits. Participants will be asked to record their pain scores and the pain medicines they take for several weeks after surgery.

The risks of joining are small and similar to those of routine care. All three pain control methods are already used in regular knee replacement surgery. Possible side effects may include temporary numbness, weakness, or soreness from the injections, and the usual surgical risks such as infection.

Participants may benefit from better pain control, less need for opioids, and a smoother recovery. The results from this study may also help future patients have safer and more comfortable knee replacements.

Taking part is voluntary. Participants can leave the study at any time without affecting their medical care.

The 3 groups in the trial

  • Periarticular InjectionExisting treatment, for comparison

    Study group I (standard PAI) will receive an intraoperative periarticular injection consisting of 300mg of 0.5% ropivacaine with 1mg epinephrine and 30mg ketorolac in sodium chloride 0.9% diluted to a volume of 120ml.

  • Adductor Canal BlockExisting treatment, for comparison

    (adductor canal block) will receive an adductor canal block in the preoperative bay.

  • Bupivacaine-MeloxicamExisting treatment, for comparison

    will receive the extended-release bupivacaine injected into the effective knee joint space prior to closure, combined with an abbreviated PAI of half dose (150mg ropivacaine) to act as a bridge per standard recommendation.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty
Plain-language title
Zynrelef compared with usual pain treatments after knee replacement for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
20 August 2026